Oct. 21, 2014, Neurology reported that Dr. Georgios Tsivgoulis’ research team from Attikon Hospital, Athens University School of Medicine, Greece, conducted a study to assess the safety and efficacy of strong antihypertensive therapy in the acute phase of cerebral hemorrhage using a systematic review and Meta-analysis. In this study, randomized controlled trials of strong antihypertensive therapy in the acute phase of cerebral hemorrhage were collected, systematically reviewed and Meta-analyzed according to PRISMA guidelines. Four eligible studies with a total of 3315 patients (mean age 63.4 ± 1.4 years, 64% male) were selected for this trial. The results of the trial showed that the mortality rate in the group randomly assigned to strong hypotension was comparable to that in the conventional hypotension group. Compared to the conventional hypotensive group, the strong hypotensive group had lower mortality and dependence in the first 3 months (modified Rankin scale grade 3-6) and, within 24 hours, significantly slowed hematoma expansion. This study concludes that strong antihypertensive treatment measures are relatively safe during the acute phase of cerebral hemorrhage. A small number of patients may experience some discomfort for 3 months after strong antihypertensive therapy. In addition, strong antihypertensive treatment during the acute phase of cerebral hemorrhage significantly slowed down the expansion of the hematoma within 24 hours.